A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Inclusion Criteria:

• Have a diagnosis of active psoriatic arthritis (PsA) as defined by a rheumatologistor other healthcare professional (HCP) experienced in treating PsA.

• Body Mass Index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity)or 27 kg/m2 to <30 kg/m² (overweight) in the presence of at least 1 weight-relatedcomorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleepapnea, or cardiovascular disease).

• Who have been treated with ixekizumab for approximately 3 months (±1 month) prior todecision to add tirzepatide.

• Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline or screening).

Exclusion Criteria:

• Have currently received ixekizumab for more than 4 months or less than 2 months.

• Had any exposure to tirzepatide or other glucagon-like peptide-1 (GLP-1) receptoragonist (for example, dulaglutide, liraglutide, or semaglutide).

• Are currently enrolled in any other clinical study.

• Have a known hypersensitivity to any component of tirzepatide.

• Have a personal or family history of medullary thyroid cancer.

• Have multiple endocrine neoplasia type 2.

• Have type 1 diabetes mellitus.

• Have a history of chronic or acute pancreatitis at any time before screening.

• Have a history of proliferative diabetic retinopathy, diabetic maculopathy, ornonproliferative diabetic retinopathy that requires acute treatment.

• Have a history of ketoacidosis or hyperosmolar state/coma.

• Have a history of severe hypoglycemia unawareness within the 6 months beforescreening.

• Have a history of severe gastrointestinal complications, including gastroparesis,gastroesophageal reflux disease, dyspepsia, chronic nausea/vomiting.